NasdaqGS - Delayed Quote • USD
SpringWorks Therapeutics, Inc. (SWTX)
At close: May 31 at 4:00 PM EDT
After hours: May 31 at 5:04 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 6 |
| Avg. Estimate | -1.12 | -1.04 | -4.6 | -3.51 |
| Low Estimate | -1.32 | -1.15 | -6.33 | -4.93 |
| High Estimate | -0.99 | -0.89 | -3.86 | -1.88 |
| Year Ago EPS | -1.25 | -1.27 | -5.15 | -4.6 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 7 |
| Avg. Estimate | 32.99M | 41.16M | 138.06M | 314.12M |
| Low Estimate | 28M | 33M | 90M | 213.6M |
| High Estimate | 38.51M | 50M | 174M | 377.2M |
| Year Ago Sales | -- | -- | 5.45M | 138.06M |
| Sales Growth (year/est) | -- | -- | 2,434.60% | 127.50% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.26 | -1.33 | -1.24 | -1.17 |
| EPS Actual | -1.25 | -1.27 | -1.45 | -1.18 |
| Difference | 0.01 | 0.06 | -0.21 | -0.01 |
| Surprise % | 0.80% | 4.50% | -16.90% | -0.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.12 | -1.04 | -4.6 | -3.51 |
| 7 Days Ago | -1.12 | -1.04 | -4.6 | -3.51 |
| 30 Days Ago | -1.16 | -1.1 | -4.72 | -3.56 |
| 60 Days Ago | 1.75 | -1.09 | -4.71 | -3.5 |
| 90 Days Ago | -1.18 | -1.08 | -4.69 | -3.38 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 2 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SWTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 10.40% | -- | -- | 8.90% |
| Next Qtr. | 18.10% | -- | -- | 11.40% |
| Current Year | 10.70% | -- | -- | 5.80% |
| Next Year | 23.70% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.45% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/31/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/6/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/6/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 3/6/2024 |
| Maintains | Barclays: Overweight to Overweight | 2/29/2024 |
| Maintains | Wedbush: Outperform to Outperform | 2/26/2024 |
Related Tickers
SNDX Syndax Pharmaceuticals, Inc.
19.24
-0.26%
KRYS Krystal Biotech, Inc.
160.05
-0.96%
DAWN Day One Biopharmaceuticals, Inc.
13.27
-2.43%
CGEM Cullinan Therapeutics, Inc.
23.50
+3.12%
MLTX MoonLake Immunotherapeutics
40.66
-0.93%
IMCR Immunocore Holdings plc
48.98
+4.86%
URGN UroGen Pharma Ltd.
13.31
-1.77%
RYTM Rhythm Pharmaceuticals, Inc.
35.68
-2.73%
NUVL Nuvalent, Inc.
65.62
-1.29%
ARVN Arvinas, Inc.
33.14
+2.79%